The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

Unseasonably high flu cases are leading to an uptick in visits to NSW emergency departments while COVID continues to increase ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

For the last several months, reports about bird flu have largely quieted -- until now. In the first human bird flu case in the U.S. since February, an older adult in Washington state was hospitalized ...

Cancer vaccines have long sounded like science fiction, but a new wave of nanoparticle research is pushing that idea closer ...